Kolon TissueGene, Inc. Logo

Kolon TissueGene, Inc.

Developing cell and gene therapies for orthopedic and degenerative disorders.

950160 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
9713 Key West Ave Suite 300, Rockville
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kolon TissueGene, Inc. is a clinical-stage biopharmaceutical company specializing in the development of advanced cell and gene therapies for orthopedic and degenerative disorders. The company's lead product candidate, TG-C, is a first-in-class, disease-modifying allogeneic cell therapy for the treatment of knee osteoarthritis. This innovative therapy is designed to reduce pain, improve joint function, and potentially slow disease progression. Kolon TissueGene is advancing TG-C through late-stage clinical trials and exploring the application of its platform technology for other degenerative conditions, such as spinal diseases.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Kolon TissueGene, Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-12 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 88.5 KB
2025-09-11 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 20.0 KB
2025-09-10 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 13.9 KB
2025-09-09 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 19.1 KB
2025-09-04 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 18.6 KB
2025-08-27 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 18.7 KB
2025-08-14 00:00
Capital/Financing Update
파생상품거래손실발생
Korean 7.8 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.3 MB
2025-07-28 00:00
Share Issue/Capital Change
[기재정정]전환청구권행사
Korean 13.1 KB
2025-07-24 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 20.3 KB
2025-07-22 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 16.7 KB

Automate Your Workflow. Get a real-time feed of all Kolon TissueGene, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Kolon TissueGene, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
WAKAMOTO PHARMACEUTICAL CO.,LTD. Logo
Develops gastrointestinal and ophthalmic drugs for the health challenges of an aging society.
Japan 4512
WELLBIOTEC CO.,LTD Logo
Diversified in biopharma, EV chargers, and lithium supply for batteries.
South Korea 010600
WHANIN PHARM CO.,LTD Logo
Develops and sells pharmaceuticals, specializing in CNS, cardiovascular, and GI drugs.
South Korea 016580
WooGeneB&GCO.,Ltd Logo
Manufactures veterinary medicines, vaccines, and supplements for livestock and aquatic animals.
South Korea 018620
Xbrane Biopharma Logo
Develops affordable biosimilars for serious diseases using patented, high-yield production tech.
Sweden XBRANE
Xintela AB Logo
Develops stem cell therapies for osteoarthritis and venous leg ulcers using proprietary technology.
Sweden XINT
Xspray Pharma Logo
Develops improved cancer drugs (PKIs) using patented tech to circumvent secondary patents.
Sweden XSPRAY
Y.B Urban Renewal - Residential Development LTD Logo Israel CSURE-M
YUHAN CORPORATION Logo
A pharmaceutical & chemical firm developing drugs, supplements, consumer products, and APIs.
South Korea 000100
YUKI GOSEI KOGYO CO.,LTD. Logo
Manufactures fine chemicals, amino acids, and APIs via organic synthesis for global industries.
Japan 4531

Talk to a Data Expert

Have a question? We'll get back to you promptly.